Related Experiment Videos

Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events

Matthias Dupont1, Yuping Wu, Stanley L Hazen

  • 1Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.

Insights

Cystatin C (CysC) improves prediction of adverse cardiovascular events in heart failure patients, especially those with preserved kidney function. This marker offers added prognostic value beyond traditional measures like creatinine.

Area of Science:

  • Cardiology
  • Nephrology
  • Biomarkers

Background:

  • Renal function is a critical predictor of adverse events in heart failure.
  • Current measures of renal function are suboptimal.
  • Cystatin C (CysC) is recognized as a superior marker for glomerular filtration rate.

Purpose of the Study:

  • To compare the prognostic utility of CysC and its derived glomerular filtration rate (GFR) estimates against other renal function markers in chronic heart failure patients.
  • To assess the incremental prognostic value of CysC in predicting major adverse cardiovascular events (MACE).

Main Methods:

  • Serum CysC levels were measured in 823 heart failure patients undergoing coronary angiography.
  • Follow-up data on MACE (death, myocardial infarction, stroke) were collected.
  • Statistical analyses included correlation, receiver operating characteristic (ROC) curves, and multivariable regression.

Main Results:

  • CysC showed strong correlations with creatinine, blood urea nitrogen, and estimated GFR (eGFR) via the MDRD equation.
  • Correlation was weaker for eGFR ≥60 mL/min/1.73 m².
  • CysC-based measures significantly improved MACE prediction, particularly in patients with eGFR ≥60 mL/min/1.73 m² (22.2% net reclassification improvement).
  • CysC was an independent predictor of MACE after adjusting for traditional risk factors and brain natriuretic peptide.

Conclusions:

  • Cystatin C is an independent predictor of adverse events in chronic heart failure.
  • CysC provides significant prognostic value beyond creatinine, especially in patients with preserved renal function.
Abstract

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.